We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M Turnover 36.96%
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
-16.4%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$515M
AUM Growth
+$40.8M
Cap. Flow
+$147M
Cap. Flow %
28.58%
Top 10 Hldgs %
82.02%
Holding
40
New
12
Increased
15
Reduced
5
Closed
4
Avg Time Held Equity + Options
1.1 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$98.8M
2
WBD icon
Warner Bros
WBD
+$25.9M
3
WK icon
Workiva
WK
+$6.97M
4
SLNO icon
Soleno Therapeutics
SLNO
+$4M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.46M

Top Sells

Rank Stock Value
1
RAPT icon
RAPT Therapeutics
RAPT
+$4.46M
2
ANNX icon
Annexon
ANNX
+$4.17M
3
FOLD icon
Amicus Therapeutics
FOLD
+$3.71M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$2.17M
5
ZVRA icon
Zevra Therapeutics
ZVRA
+$1.72M

Sector Composition

Rank Sector Weight
1 Technology 62.65%
2 Healthcare 23.94%
3 Energy 7.28%
4 Communication Services 4.92%
5 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PATH icon
1
UiPath
PATH
$6.94B
$280M 54.32%
25,207,628
+7,757,628
+44% +$98.8M
2022 Q1
16 quarters
KGEI icon
2
Kolibri Global Energy
KGEI
$230M
$37.5M 7.28%
6,834,504
-100,000
-1% -$422K
2023 Q4
9 quarters
WBD icon
3
DELISTED
Warner Bros
WBD
$25.4M 4.92%
+923,725
New +$25.9M
2026 Q1
0 quarters
WK icon
4
Workiva
WK
$4.15B
$14.9M 2.89%
250,000
+100,000
+67% +$6.97M
2025 Q2
3 quarters
LYFT icon
5
Lyft
LYFT
$6.24B
$13.3M 2.58%
1,000,000
– –
2021 Q4
17 quarters
CXM icon
6
Sprinklr
CXM
$1.35B
$13.2M 2.56%
2,200,000
– –
2022 Q1
16 quarters
AUTL icon
7
Autolus Therapeutics
AUTL
$452M
$13.1M 2.55%
9,500,000
– –
2018 Q2
31 quarters
CLDX icon
8
Celldex Therapeutics
CLDX
$2.23B
$9.91M 1.92%
312,316
+68,516
+28% +$1.87M
2024 Q4
5 quarters
ARWR icon
9
Arrowhead Research
ARWR
$8.23B
$7.98M 1.55%
127,198
+30,263
+31% +$1.92M
2025 Q3
2 quarters
NKTR icon
10
Nektar Therapeutics
NKTR
$1.3B
$7.41M 1.44%
103,037
+33,750
+49% +$1.92M
2025 Q4
1 quarter
ANNX icon
11
Annexon
ANNX
$692M
$7.16M 1.39%
1,292,455
-740,000
-36% -$4.17M
2024 Q2
7 quarters
PHVS icon
12
Pharvaris
PHVS
$2.11B
$6.26M 1.22%
221,611
+26,999
+14% +$721K
2025 Q1
4 quarters
AXSM icon
13
CALL
Axsome Therapeutics
AXSM
$8.72B
$5.92M 1.15%
+35,000
New +$6.05M
2026 Q1
0 quarters
ALKS icon
14
Alkermes
ALKS
$6.74B
$5.65M 1.1%
159,791
+18,619
+13% +$578K
2025 Q2
3 quarters
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.9B
$5.58M 1.08%
164,839
+2,821
+2% +$80K
2025 Q4
1 quarter
IMVT icon
16
Immunovant
IMVT
$5.77B
$5.43M 1.05%
218,507
+52,320
+31% +$1.35M
2025 Q1
4 quarters
PRAX icon
17
Praxis Precision Medicines
PRAX
$6.94B
$5.14M 1%
15,952
-7,000
-30% -$2.17M
2025 Q4
1 quarter
KRYS icon
18
Krystal Biotech
KRYS
$9.86B
$5.08M 0.99%
19,668
+7,854
+66% +$2.09M
2025 Q3
2 quarters
DYN icon
19
Dyne Therapeutics
DYN
$2.85B
$4.68M 0.91%
258,132
+10,135
+4% +$175K
2025 Q2
3 quarters
AMLX icon
20
Amylyx Pharmaceuticals
AMLX
$3.49B
$4.42M 0.86%
317,877
+45,049
+17% +$634K
2025 Q2
3 quarters
MBX icon
21
MBX Biosciences
MBX
$2.42B
$4.34M 0.84%
145,480
+2,153
+2% +$73.2K
2025 Q3
2 quarters
DFTX icon
22
Definium Therapeutics
DFTX
$4.59B
$3.78M 0.73%
+199,994
New +$3.39M
2026 Q1
0 quarters
SLNO icon
23
DELISTED
Soleno Therapeutics
SLNO
$3.42M 0.66%
+102,125
New +$4M
2026 Q1
0 quarters
AXSM icon
24
Axsome Therapeutics
AXSM
$8.72B
$3.39M 0.66%
20,059
-6,875
-26% -$1.19M
2024 Q4
5 quarters
HRMY icon
25
Harmony Biosciences
HRMY
$2.25B
$3.34M 0.65%
119,340
+36,516
+44% +$1.2M
2025 Q4
1 quarter
1
2

Similar funds

GRR
Golden Reserve Retirement Dublin, Ohio $635M AUM 25.04% 1-Year Est. Return
GAM
Gould Asset Management Claremont, California $635M AUM 14.36% 1-Year Est. Return
MPIA
Mountain Pacific Investment Advisers Boise, Idaho $635M AUM 26.7% 1-Year Est. Return
AFG
Altiora Financial Group Lebanon, Ohio $634M AUM 13.93% 1-Year Est. Return
MCM
Maytus Capital Management New York $636M AUM 131.32% 1-Year Est. Return
MAM
Milestone Asset Management Pittsburgh, Pennsylvania $636M AUM 22.1% 1-Year Est. Return
BAM
BOCHK Asset Management Hong Kong $634M AUM 64.99% 1-Year Est. Return
LRIA
Leonard Rickey Investment Advisors Yakima, Washington $637M AUM 25.11% 1-Year Est. Return

TFG Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, TFG Asset Management held 40 positions worth $515M, up 8.6% from $474M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

TFG Asset Management deployed $147M of net new capital in Q1 2026, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was Warner Bros: 923,725 shares worth $25.4M.

By sector, the portfolio is most concentrated in Technology at 63% of assets, down from 71% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Annexon, an estimated $4.17M trimmed.

  • TFG Asset Management's largest Q1 2026 buy was Warner Bros: 923,725 shares worth $25.4M.
  • TFG Asset Management added most to UiPath in Q1 2026, an estimated $98.8M increase.
  • TFG Asset Management's biggest Q1 2026 reduction was Annexon, cutting an estimated $4.17M.
  • TFG Asset Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $4.46M.
  • TFG Asset Management's ten largest holdings make up 82% of its $515M portfolio in Q1 2026.
  • TFG Asset Management opened 12 new positions and closed 4 in Q1 2026.
  • TFG Asset Management's portfolio value rose 8.6% quarter-over-quarter to $515M.

Based on TFG Asset Management's 13F filing for Q1 2026, filed 15 May 2026.